BioCentury | Feb 25, 2020
Distillery Therapeutics

Promoting CX3CL1 expression to treat Alzheimer's

...overexpression also prevented learning and memory impairments and extended survival in the AD model. TARGET/MARKER/PATHWAY: Chemokine CX3C motif...
...Cleveland Clinic Foundation, Cleveland, Ohio; University of Connecticut Health, Farmington, Conn. email: riyan@uchc.edu Claire Quang Cleveland Clinic Foundation Chemokine CX3C motif...
BioCentury | Sep 4, 2019
Preclinical News

Preclinical Quick Takes: NIH's clinical trial practices in preclinical studies, plus Kancera and optimized base editors

...Edits" ). Targets: APOBEC1 - Apoliprotein B mRNA editing enzyme catalytic subunit 1; CX3CR1 - Chemokine CX3C motif...
...Editor Beam Therapeutics Kancera AB Massachusetts General Hospital National Institutes of Health Apoliprotein B mRNA editing enzyme catalytic subunit 1 (APOBEC1) Chemokine CX3C motif...
BioCentury | May 6, 2019
Distillery Therapeutics

CX3CL1 gene therapy for retinitis pigmentosa

...steps could include testing CX3CL1 gene therapy in larger animal models of retinitis pigmentosa. TARGET/MARKER/PATHWAY: Chemokine CX3C motif...
...2019 doi:10.1073/pnas.1901787116 CONTACT: Constance L. Cepko, Harvard Medical School, Boston, Mass. email: cepko@genetics.med.harvard.edu Claire Quang Harvard Medical School Chemokine CX3C motif...
BioCentury | Mar 2, 2018
Clinical News

Kancera's KAND567 well tolerated in Phase I

...800 mg dose of KAND567. Kancera has rights to the oral small molecule inhibitor of chemokine CX3C motif...
...AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: KAND567 (AZD8797) Business: Cancer, Inflammation, Cardiovascular Molecular target: Chemokine CX3C motif...
BioCentury | Mar 29, 2017
Distillery Therapeutics

Endocrine / Metabolic

...or empty vector. Next steps could include testing CX3CL1 in additional models of obesity. TARGET/MARKER/PATHWAY: Chemokine CX3C motif...
...2017 doi:10.1038/ncomms14556 CONTACT: Joshua P. Thaler, University of Washington, Seattle, Wash. email: jpthaler@uw.edu Mary Romeo University of Washington Chemokine CX3C motif...
BioCentury | Feb 28, 2017
Distillery Therapeutics

Infectious disease

...In a human monocyte cell line expressing US28, a fusion protein consisting of the US28-binding chemokine CX3C motif...
...U.K. email: back2@cam.ac.uk CONTACT: J. H. Sinclair, same affiliation as above email: js@mole.cam.ac.uk Hongjiang Li University of Cambridge Chemokine CX3C motif...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Chemokine CX3C motif receptor 1 (CX3CR1)

...have an anti-CX3CR1 nanobody in Phase I testing to treat chronic kidney disease (CKD). TARGET/MARKER/PATHWAY: Chemokine CX3C motif...
BioCentury | Apr 25, 2016
Clinical News

Anti-CX3CR1 Nanobody: Phase I started

...Germany Product: Anti-CX3CR1 Nanobody Business: Renal Molecular target: Chemokine CX3C motif receptor 1 (CX3CR1) Description: Nanobody against chemokine CX3C motif...
BioCentury | Jul 23, 2015
Distillery Therapeutics

Therapeutics: CMV CC chemokine receptor (US28)

...Chemical synthesis and in vitro testing of chemokine-toxin fusion proteins identified a compound consisting of chemokine CX3C motif...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Interleukin-1 (IL-1) β; IL-1 receptor; purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

...studies suggest inhibiting P2RX7 or IL-1β/IL-1 receptor signaling could help treat AMD. Subretinal accumulation of chemokine CX3C motif...
Items per page:
1 - 10 of 22